Stoke Therapeutics, Inc. Common Stock (STOK)
PHARMACEUTICAL PREPARATIONS
Stoke Therapeutics, Inc. Common Stock (STOK) is listed on Nasdaq, where it has traded since June 19, 2019.
- Listed On
- Nasdaq
- Listed Since
- June 19, 2019
- Employees
- 170
- Market Cap
- $1.7B
About Stoke Therapeutics, Inc. Common Stock
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 189 institutions reported holding STOK, with 76.2 million shares worth $2.5 billion in aggregate. The largest reported holder was BlackRock, with 5.9 million shares worth $192.3 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 5,877,357 | $192M | Added 9.13% |
| Rtw Investments | 5,623,525 | $184M | Unchanged |
| FMR | 5,313,100 | $174M | Reduced 1.31% |
| T. Rowe Price | 5,076,878 | $166M | Added 132.34% |
| Lynx1 Capital Management | 4,038,404 | $132M | Reduced 15.22% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is STOK?
Stoke Therapeutics, Inc. Common Stock (STOK) is listed on Nasdaq, where it has traded since June 19, 2019.
Who are the largest institutional holders of STOK?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of STOK were BlackRock, Rtw Investments and FMR.
How many institutions own STOK?
189 institutions reported a position in STOK for the quarter ended June 30, 2026, worth $2.5 billion in total.
Did institutions buy or sell STOK last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for STOK.
Every reported institutional holder, plus insider and congressional trades in STOK, on SentiSense.